Scientific Program

Thursday, October 27
17:30–18:00 Industry-supported Meet the Expert Session
18:30 Welcome Reception
Friday, October 28
HALL A
09:00–10:30 Session 1: Opening Session-CAR vs. HSCT
09:00–09:10 Welcome note: Nicolaus Kröger, Germany; Arnon Nagler, Israel
09:10–09:40 Controversy: Does CAR T cell replace stem cell transplantation in DLBCL?
Chair: Nicolaus Kröger, Germany
09:10–09:25 Yes: Anna Sureda, Spain
09:25–09:40 No: Michael Bishop, USA
09:40–10:00 Controversy: Will CAR-T-cell replace stem cell transplantation in MM?
Chair: Arnon Nagler, Israel
09:40–09:55 Yes: Noopur Raje, USA
09:55–10:10 No: Philippe Moreau, France
10:10–10:30 Panel discussion: All
10:30–11:00 Coffee Break, Poster Viewing and Visit Exhibition
HALL A HALL B
11:00–12:30 Session 2: AML Session 3: Infection complications
11:00–11:30 Controversy: Should MRD positivity targeted prior SCT or after SCT?
Chair: Yi-Bin Chen, USA
Controversy: Letermovir prophylaxis as secondary prophylaxis?
Chair: Rafael de la Cámara, Spain
11:00–11:15 Prior: Arnon Nagler, Israel Yes: Michael Boeckh, USA
11:15–11:30 After: Michael Heuser, Germany No: Per Ljungman, Sweden
11:30–12:00 Controversy: Narrow vs. broad (specific vs. nonspecific) TKI post Allo in FLT3+AML
Chair: Andreas Burchert, Germany
Controversy: Are there evidence-based arguments for a general compulsory SarsCoV2 vaccinations?
Chair: Per Ljungman, Sweden
11:30–11:45 Broad: Xiaojun Huang, China Yes: Simone Cesaro, Italy
11:45–12:00 Narrow: Yi-Bin Chen, USA No: TBA
12:00–12:30 Panel discussion: All Panel discussion: All
12:30–13:00 Lunch Pick-up, Poster Viewing and Visit Exhibition
13:00–14:00 Industry-supported Symposium
14:00–14:15 Short Break
HALL A HALL B
14:15–15:45 Session 4: GVHD prophylaxis /Treatment (1) Session 5: MDS
14:15–14:45 Controversy: Is there still a role for T cell depletion (CD34 purification) as GVHD prophylaxis in HLA matched (MSD and MUD) Allograft?
Chair: Leonido Luznik, USA
Controversy: Are sequential conditioning regimens the standard for MDS EB1 and EB2?
Chair: Bart Lee Scott, USA
14:15–14:30 Yes: Miguel Perales, USA Yes: Thomas Schroeder, Germany
14:30–14:45 No: Marcelo Pasquini, USA No: Avichai Shimoni, Israel
14:45–15:15 Controversy: Can we modify schedule or dosing of PTCy?
Chair: Marcelo Pasquini, USA
Controversy: Is the new Molecular IPSS helpful for decision making regarding allo?
Chair: Avichai Shimoni, Israel
14:45–15:00 Yes: Christopher Kanakry, USA Yes: Matteo Della Porta, Italy
15:00–15:15 No: Leonido Luznik, USA No: Bart Lee Scott, USA
15:15–15:45 Panel discussion: All Panel discussion: All
15:45–16:15 Coffee Break, Poster Viewing and Visit Exhibition
16:15–17:15 Industry-supported Symposium
17:15–17:30 Short Break
HALL A HALL B
17:30–19:00 Session 6: GVHD prophylaxis/ Treatment (2) Session 7: ALL
17:30–18:00 Controversy: Do novel agents replace ECP as second line treatment in cGvHD?
Chair: Steven Pavletic, USA
Controversy: Is lower than 12 Gy TBI dose justified as conditioning for allo in young adult ALL?
Chair: Sebastian Giebel, Poland
17:30–17:45 Yes: Daniel Wolff, Germany Yes: Alexandros Spyridonidis, Greece
17:45–18:00 No: Hildegard Greinix, Austria No: David Marks, UK
18:00–18:30 Controversy: Is CNI plus antimetabolite still the standard GvHD prophylaxis for MUD in 2022?
Chair: Hildegard Greinix, Austria
Controversy: Is there still a place for upfront allo in Ph+ ALL?
Chair: David Marks, UK
18:00–18:15 Yes: Robert Zeiser, Germany Yes: Matthias Stelljes, Germany
18:15–18:30 No: Corey Cutler, USA No: Robin Foà, Italy
18:30–19:00 Panel discussion: All Panel discussion: All
Saturday, October 29
HALL A HALL B
08:00–09:30 Session 8: Acute Leukemia and CARs Session 9: SAA and VOD
08:00–08:30 Controversy: Can CAR T cell therapy replace allo SCT in adult ALL?
Chair: Arnon Nagler, Israel
Controversy: Can allogeneic SCT with 10/10 MUD be used as first line therapy for sAA?
Chair: Carlo Dufour, Italy
08:00–08:15 Yes: Claire Roddie, UK Yes: Andrea Bacigalupo, Italy
08:15–08:30 No: Sebastian Giebel, Poland No: Antonio Risitano, Italy
08:30–09:00 Controversy: Is there a role of CAR T cell or therapy in AML in 2022?
Chair: Marion Subklewe, Germany
Controversy: Is there any advantage in using the EBMT adult severity grading criteria prior to a diagnosis of VOD?
Chair: TBA
08:30–08:45 Yes: Saar Gill, USA Yes: Antonio Pagliuca, UK
08:45–09:00 No: Charles Craddock, UK No: Francesca Bonifazi, Italy
09:00–09:30 Panel discussion: All Panel discussion: All
09:30–10:00 Coffee Break, Poster Viewing and Visit Exhibition
10:00–11:00 Industry-supported Symposium
11:00–11:15 Short Break
HALL A HALL B
11:15–12:45 Session 10: Multiple Myeloma Session 11: Lymphoma/ Lymphatic malignancies
11:15–11:45 Controversy: CAR vs. Bites in R/R MM
Chair: Sergio Giralt, USA
Controversy: NHL-patients achieving <PR 6 mo post CAR should we go Allo?
Chair: David Porter, USA
11:15–11:30 CAR: Ibrahim Yakoub-Agha, France Yes: Peggy Lu, China
11:30–11:45 BITEs: Hermann Einsele, Germany No: TBA
11:45–12:15 Controversy: Is it still justified to collect CD34 cells for 2 or more transplants in MM?
Chair: Hartmut Goldschmidt, Germany
Controversy: Is there a role for cellular therapies in CAR-T .. CLL?
Chair: TBA
11:45–12:00 Yes: Pieter Sonneveld, Netherlands Yes: David Porter, USA
12:00–12:15 No: Sergio Giralt, USA No: TBA
12:15–12:45 Panel discussion: All Panel discussion: All
12:45–13:15 Lunch Pick-up, Poster Viewing and Visit Exhibition
13:15–14:15 Industry-supported Symposium
14:15–14:30 Short Break
HALL A HALL B
14:30–16:00 Session 12: Myelofibrosis Session 13: Pediatric ALL
14:30–15:00 Controversy: Does mutation panel dictate Allo indication in myelofibrosis?
Chair: Alessandro Rambaldi, Italy
Controversy: For pediatric ALL relapsing post CD19 CAR should we go to an alternative CAR?
Chair: Christina Peters, Austria
14:30–14:45 Yes: Francesco Passamonti, Italy Yes: Alan Wayne, USA
14:45–15:00 No: Nicolaus Kröger, Germany No: Peter Bader, Germany
15:00–15:30 Controversy: Is there a role for haplo or cord blood transplantation in in myelofibrosis?
Chair: Nicolaus Kröger, Germany
Controversy: Can PBSC be used as stem cell source in MUD pediatric ALL?
Chair: Alan Wayne, USA
15:00–15:15 Yes: Alessandro Rambaldi, Italy Yes: Christina Peters, Austria
15:15–15:30 No: Nico Gagelmann, Germany No: Michael Pulsipher, USA
15:30–16:00 Panel discussion: All Panel discussion: All
16:00–16:30 Coffee Break, Poster Viewing and Visit Exhibition
16:30–17:30 Industry-supported Symposium
17:30–17:45 Short Break
HALL A HALL B
17:45–19:15 Session 14: Stem cell donors Session 15: Hemoglobinopathy
17:45–18:15 Controversy: Can expanded CBT compete with Haplo SCT?
Chair: Vanderson Rocha, Brazil
Controversy: Is PTCY the preferred GvHD prophylaxis after haplo-ident SCT in sickle cell anemia?
Chair: Rupert Handgretinger, Germany
18:15–18:30 Yes: Guillermo Sanz, Spain Yes: Josu de la Fuente, UK
18:30–18:45 No: Francesca Bonifazi, Italy No: Selim Corbacioglu, Germany
18:45–19:15 Controversy: Is PBSC as stem cell source equal to BM after Haplo PTCy?
Chair: Francesca Bonifazi, Italy
Controversy: Can gene therapy replace allogeneic SCT in thalassemia?
Chair: Selim Corbacioglu, Germany
18:45–19:00 Yes: Vanderson Rocha, Brazil Yes: Rupert Handgretinger, Germany
19:00–19:15 No: TBA No: Suradej Hongeng, Thailand
19:15–19:45 Panel discussion: All Panel discussion: All
19:45–20:30 COSTEM Poster Walk and Awards
Sunday, October 30
HALL A
09:00–10:30 Session 16: Cellular therapies
09:00–09:30 Controversy: Can allo NK CAR complete with auto CAR T?
Chair: Harry Dolstra, Netherlands
09:00–09:15 Yes: Evelyn Ullrich, Germany
09:15–09:30 No: TBA
09:30–10:00 Controversy: Is the point of care production for CAR T cell the future?
Chair: TBA
09:30–09:45 Yes: Alvaro Urbano-Ispizua, Spain
09:45–10:00 No: Harry Dolstra, Netherlands
10:00–10:30 Panel discussion: All
10:30–11:00 Coffee Break
11:00–12:30 Session 17: Selection of CAR T cells
11:00–11:30 Controversy: Should we preference a CD19 CAR construct in RR DLBCL?
Chair: TBA
11:00–11:15 Yes: Wolfgang Bethge, Germany
11:15–11:30 No: Marion Subklewe, Germany
11:30–12:00 Controversy: Should we preference a BMCA CAR construct in R/R myeloma?
Chair: Hermann Einsele, Germany
11:30–11:45 Yes: Michael Hudecek, Germany
11:45–12:00 No: He Huang, China
12:00–12:30 Panel discussion: All
12:30 Closing remarks: Nicolaus Kröger, Germany; Arnon Nagler, Israel